Evidence-based reimbursement decisions and the role of formal cost-effectiveness assessments
Understand the advantages and the impact of your products in the context of the national health systems, from a pricing/health outcomes perspective. Some of the evidence-based reimbursement decision are based on a few key items which will need to be defined for your product such as:
- Efficient and “cost-effective” utilization of scarce (health care) resources as an important policy objective in the presence of limited budgets and opportunity costs
- Effective delivery against a multitude of implicitly or explicitly articulated objectives for which decision makers are politically accountable i.e. not simply the maximization of QALYs
- Trade-offs between patient groups and their different needs in the presence of a multitude of potentially conflicting health care policy objectives
- Formal health economic evaluation methodology can play a valuable role when selecting the most [technically/productively] efficient technology:–to achieve a defined clinical goal with a minimum amount of resources or–to maximize a specific clinical outcome from a defined budgetas long as the very same patient population is affected (e.g. assess the “relative value of money” of different screening programs for colorectal cancer).
Pharma Design produces a range of Market Research in EU28 and potentially some RoW countries to help you scope your business strategy ahead of competitors. We also produce other reports including scientific story flow validation, new approvals impact, prescription and OTC data, general insights from physician’s behavior, competitor activity, perceived value of new therapies, value drivers and barriers, prescribers perceptions and many more.